Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Gilead Sciences, Inc. (NASDAQ ... I'll now hand the call over to Jackie Ross, Vice President of Investor Relations and Corporate Strategic Finance. Jackie Ross : Thank you, Rebecca. Just after market ...

Revenue from collaborative research was $6.8 million for the three months ended September 30, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions) I'll now hand the ...

Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name ...